MCID: DXR001
MIFTS: 37

Doxorubicin Induced Cardiomyopathy malady

Categories: Rare diseases, Cardiovascular diseases

Aliases & Classifications for Doxorubicin Induced Cardiomyopathy

Aliases & Descriptions for Doxorubicin Induced Cardiomyopathy:

Name: Doxorubicin Induced Cardiomyopathy 50

Classifications:



Summaries for Doxorubicin Induced Cardiomyopathy

MalaCards based summary : Doxorubicin Induced Cardiomyopathy is related to cardiomyopathy and hypogonadotropic hypogonadism 16 with or without anosmia. An important gene associated with Doxorubicin Induced Cardiomyopathy is GATA4 (GATA Binding Protein 4), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Doxorubicin and Doxil have been mentioned in the context of this disorder. Affiliated tissues include heart, bone and bone marrow, and related phenotypes are Decreased cell migration and Decreased substrate adherent cell growth

Related Diseases for Doxorubicin Induced Cardiomyopathy

Graphical network of the top 20 diseases related to Doxorubicin Induced Cardiomyopathy:



Diseases related to Doxorubicin Induced Cardiomyopathy

Symptoms & Phenotypes for Doxorubicin Induced Cardiomyopathy

GenomeRNAi Phenotypes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.56 EGFR EPHB2 MAPK14 MET
2 Decreased substrate adherent cell growth GR00193-A-2 9.33 EGFR EPHB2 MAPK14
3 Decreased viability after Chlamydia trachomatis serovar L2 infection and TNF-alpha/CHX stimulation GR00206-A 8.96 MET MAPK14
4 Increased cell viability after pRB stimulation GR00230-A-1 8.8 EGFR MAPK14 MET

MGI Mouse Phenotypes related to Doxorubicin Induced Cardiomyopathy:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.16 CNR1 DES EGFR EPHB2 EPOR GATA4
2 cardiovascular system MP:0005385 10.13 DES ECE1 EGFR EPOR GATA4 HGF
3 growth/size/body region MP:0005378 10.11 HGF MAPK14 MET CNR1 ECE1 EGFR
4 embryo MP:0005380 10.02 ECE1 EGFR EPOR GATA4 HGF MAPK14
5 mortality/aging MP:0010768 10.02 ECE1 EGFR EPHB2 EPOR GATA4 HGF
6 hematopoietic system MP:0005397 9.98 CSF3 ECE1 EGFR EPOR GATA4 HGF
7 digestive/alimentary MP:0005381 9.97 CNR1 ECE1 EGFR EPHB2 GATA4 MET
8 integument MP:0010771 9.88 CNR1 CSF3 ECE1 EGFR GATA4 MAPK14
9 liver/biliary system MP:0005370 9.85 EGFR EPOR GATA4 HGF MAPK14 MET
10 nervous system MP:0003631 9.76 CNR1 ECE1 EGFR EPHB2 EPOR GATA4
11 muscle MP:0005369 9.73 ECE1 EGFR GATA4 MAPK14 MET DES
12 no phenotypic analysis MP:0003012 9.43 CNR1 EGFR EPOR GATA4 HGF MET
13 normal MP:0002873 9.17 CNR1 ECE1 EGFR EPOR GATA4 MAPK14

Drugs & Therapeutics for Doxorubicin Induced Cardiomyopathy

Drugs for Doxorubicin Induced Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
2
Doxil Approved June 1999 Phase 2, Phase 3 31703
3 Topoisomerase Inhibitors Phase 2, Phase 3
4 Anti-Bacterial Agents Phase 2, Phase 3
5 Antibiotics, Antitubercular Phase 2, Phase 3
6
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
7
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
8 Albumin-Bound Paclitaxel Phase 2
9
Menthol Approved 2216-51-5 16666
10 Chelating Agents
11 Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate

Interventional clinical trials:


id Name Status NCT ID Phase
1 Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients Unknown status NCT02078388 Phase 2, Phase 3
2 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer Active, not recruiting NCT02677714 Phase 2
3 Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients Completed NCT03000036
4 Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy Recruiting NCT02796365

Search NIH Clinical Center for Doxorubicin Induced Cardiomyopathy

Genetic Tests for Doxorubicin Induced Cardiomyopathy

Anatomical Context for Doxorubicin Induced Cardiomyopathy

MalaCards organs/tissues related to Doxorubicin Induced Cardiomyopathy:

39
Heart, Bone, Bone Marrow, Testes, Myeloid, Pituitary

Publications for Doxorubicin Induced Cardiomyopathy

Articles related to Doxorubicin Induced Cardiomyopathy:

(show top 50) (show all 132)
id Title Authors Year
1
Correction to: "Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy." ( 28087848 )
2017
2
Sarco"MiR" friend or foe: a perspective on the mechanisms of doxorubicin-induced cardiomyopathy. ( 27294099 )
2016
3
Protective effect of Co-enzyme Q10 On doxorubicin-induced cardiomyopathy of rat hearts. ( 27087047 )
2016
4
Obestatin attenuated doxorubicin-induced cardiomyopathy via enhancing long noncoding Mhrt RNA expression. ( 27261628 )
2016
5
Matricellular protein CCN1 mediates doxorubicin-induced cardiomyopathy in mice. ( 27167338 )
2016
6
Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. ( 26873966 )
2016
7
Yogurt Containing the Probacteria Lactobacillus acidophilus Combined with Natural Antioxidants Mitigates Doxorubicin-Induced Cardiomyopathy in Rats. ( 25590792 )
2015
8
Potent Paracrine Effects of human induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells Attenuate Doxorubicin-induced Cardiomyopathy. ( 26057572 )
2015
9
Shengmai injection improved Doxorubicin-induced cardiomyopathy by alleviating myocardial endoplasmic reticulum stress and caspase-12 dependent apoptosis. ( 25839043 )
2015
10
Astragalus polysaccharide improves cardiac function in doxorubicin-induced cardiomyopathy through ROS-p38 signaling. ( 26885153 )
2015
11
Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy. ( 25660617 )
2015
12
Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy. ( 26511374 )
2015
13
Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice. ( 26191652 )
2015
14
Cyclovirobuxine D Attenuates Doxorubicin-Induced Cardiomyopathy by Suppression of Oxidative Damage and Mitochondrial Biogenesis Impairment. ( 26075032 )
2015
15
A metabolomic study of rats with doxorubicin-induced cardiomyopathy and Shengmai injection treatment. ( 25938766 )
2015
16
Heart rate dynamics in doxorubicin-induced cardiomyopathy. ( 25798626 )
2015
17
Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. ( 25569804 )
2015
18
Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. ( 25504881 )
2014
19
Embryonic Stem Cells and Released Factors Stimulate c-kit (+ve) /FLK-1(+ve) Progenitor Cells and Promote Neovascularization in Doxorubicin-induced Cardiomyopathy. ( 24593859 )
2014
20
Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. ( 24486195 )
2014
21
Arginase inhibition augments nitric oxide production and facilitates left ventricular systolic function in doxorubicin-induced cardiomyopathy in mice. ( 25263201 )
2014
22
Cardioprotective effect of ammonium glycyrrhizinate against doxorubicin-induced cardiomyopathy in experimental animals. ( 25298583 )
2014
23
Therapeutic use of H2O2-responsive anti-oxidant polymer nanoparticles for doxorubicin-induced cardiomyopathy. ( 24767791 )
2014
24
Increased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat. ( 23741376 )
2013
25
Macrophage migration inhibitory factor deficiency augments doxorubicin-induced cardiomyopathy. ( 24334905 )
2013
26
Manipulation of Cardiac PI3K/Akt Signaling by Apoptosis regulator through modulating IAP expression (ARIA) Regulates Cardiomyocyte Death during the Doxorubicin-induced Cardiomyopathy. ( 24338479 )
2013
27
The beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy. ( 23731918 )
2013
28
Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats. ( 24228260 )
2013
29
Effects of Histidine and N-Acetylcysteine on Doxorubicin-Induced Cardiomyopathy in Rats. ( 24343415 )
2013
30
Interrelation between Expression of ADAM 10 and MMP 9 and Synthesis of Peroxynitrite in Doxorubicin Induced Cardiomyopathy. ( 24244825 )
2013
31
Embryonic stem cells improve cardiac function in Doxorubicin-induced cardiomyopathy mediated through multiple mechanisms. ( 22449713 )
2012
32
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. ( 22465037 )
2012
33
Effects of the antioxidant agent tempol on periapical lesions in rats with doxorubicin-induced cardiomyopathy. ( 22244634 )
2012
34
Discordant impairment of multidirectional myocardial deformation in rats with Doxorubicin induced cardiomyopathy. ( 22486544 )
2012
35
Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. ( 22719160 )
2012
36
Fosinopril attenuates the doxorubicin-induced cardiomyopathy by restoring the function of sarcoplasmic reticulum. ( 22729889 )
2012
37
Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. ( 22808256 )
2012
38
S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling. ( 22039489 )
2011
39
Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks. ( 21330293 )
2011
40
Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its application. ( 22110719 )
2011
41
Bovine model of doxorubicin-induced cardiomyopathy. ( 21253525 )
2011
42
Inorganic nitrate therapy improves Doxorubicin-induced cardiomyopathy a new window for an affordable cardiovascular therapy for everyone? ( 21596235 )
2011
43
Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. ( 21946105 )
2011
44
Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. ( 21624372 )
2011
45
Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation ofA mitochondrial function. ( 21094500 )
2011
46
Dietary nitrate supplementation protects against Doxorubicin-induced cardiomyopathy by improving mitochondrial function. ( 21596234 )
2011
47
Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. ( 20978005 )
2011
48
Attenuation of Doxorubicin-induced cardiomyopathy by endothelin-converting enzyme-1 ablation through prevention of mitochondrial biogenesis impairment. ( 20101000 )
2010
49
Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198). ( 20668052 )
2010
50
CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. ( 19942623 )
2010

Variations for Doxorubicin Induced Cardiomyopathy

Expression for Doxorubicin Induced Cardiomyopathy

Search GEO for disease gene expression data for Doxorubicin Induced Cardiomyopathy.

Pathways for Doxorubicin Induced Cardiomyopathy

Pathways related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 31)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.58 CSF3 DES EGFR EPHB2 EPOR HGF
2
Show member pathways
13.47 EGFR EPHB2 EPOR GATA4 HGF MAPK14
3
Show member pathways
13.34 EGFR EPHB2 EPOR HGF MAPK14 MET
4
Show member pathways
13.32 EGFR EPHB2 EPOR HGF MAPK14 MET
5
Show member pathways
13.12 EGFR EPHB2 EPOR HGF MET
6
Show member pathways
13.09 CSF3 ECE1 EGFR EPHB2 EPOR HGF
7
Show member pathways
13.02 EGFR EPHB2 EPOR HGF MAPK14 MET
8
Show member pathways
13.01 CSF3 EGFR EPHB2 EPOR HGF MAPK14
9
Show member pathways
12.83 EGFR EPHB2 HGF MAPK14 MET
10
Show member pathways
12.77 EGFR EPHB2 EPOR MAPK14 MET
11
Show member pathways
12.71 EGFR EPOR MAPK14 MET
12
Show member pathways
12.71 EGFR HGF MAPK14 MET
13
Show member pathways
12.67 EGFR EPOR GATA4 MAPK14
14
Show member pathways
12.47 CNR1 EGFR HGF MAPK14 MET
15
Show member pathways
12.18 HGF MAPK14 MET
16 12.09 EGFR HGF MAPK14 MET
17 11.92 EGFR EPHB2 MET
18 11.89 GATA4 HGF MET
19 11.86 EGFR HGF MET
20
Show member pathways
11.66 EGFR HGF MET
21 11.56 CSF3 EGFR EPOR HGF MET
22 11.32 CSF3 HGF MET
23
Show member pathways
11.2 EGFR HGF MET
24 11.15 EGFR HGF MET
25 11.12 EGFR MET
26 11.05 EGFR EPOR
27 11.03 CSF3 HGF MAPK14
28 11 GATA4 MAPK14
29 10.96 EGFR HGF MET
30 10.81 HGF MET
31 10.61 EGFR HGF MET

GO Terms for Doxorubicin Induced Cardiomyopathy

Cellular components related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.17 CSF3 EGFR EPHB2 EPOR HGF MAPK14

Biological processes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.84 EGFR EPHB2 MAPK14 MET
2 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.8 CSF3 EGFR GATA4 HGF MAPK14 MET
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.67 EGFR EPHB2 MET
4 MAPK cascade GO:0000165 9.67 EGFR HGF MAPK14 MET
5 phosphatidylinositol-mediated signaling GO:0048015 9.65 EGFR HGF MET
6 phosphatidylinositol phosphorylation GO:0046854 9.61 EGFR HGF MET
7 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.58 EGFR HGF MET
8 peptidyl-tyrosine phosphorylation GO:0018108 9.56 EGFR EPHB2 HGF MET
9 positive chemotaxis GO:0050918 9.52 HGF MET
10 axonal fasciculation GO:0007413 9.51 CNR1 EPHB2
11 hepatocyte growth factor receptor signaling pathway GO:0048012 9.46 HGF MET
12 negative regulation of autophagy GO:0010507 9.33 GATA4 HGF MET
13 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 8.96 HGF MET
14 cell morphogenesis GO:0000902 8.92 EGFR EPHB2 HGF MAPK14

Molecular functions related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.71 EGFR EPHB2 MAPK14 MET
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.54 EGFR HGF MET
3 protein phosphatase binding GO:0019903 9.5 EGFR MAPK14 MET
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.43 EGFR HGF MET
5 NFAT protein binding GO:0051525 9.16 GATA4 MAPK14
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR EPHB2 MET
7 protein tyrosine kinase activity GO:0004713 8.92 EGFR EPHB2 HGF MET

Sources for Doxorubicin Induced Cardiomyopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....